Equities
  • Price (EUR)75.45
  • Today's Change0.26 / 0.35%
  • Shares traded0.00
  • 1 Year change+22.76%
  • Beta--
Data delayed at least 15 minutes, as of Nov 28 2022 18:37 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland, and Japanese office in Tokyo and Canadian headquarters in Montreal. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream.

  • Revenue in USD (TTM)3.33bn
  • Net income in USD876.05m
  • Incorporated1991
  • Employees2.09k
  • Location
    Incyte Corp1801 Augustine Cut-OffWILMINGTON 19803United StatesUSA
  • Phone+1 (302) 498-6700
  • Fax+1 (302) 636-5454
  • Websitehttps://www.incyte.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
INCY:NSQ since
announced
Transaction
value
Villaris Therapeutics IncAnnounced03 Oct 202203 Oct 2022Announced17.05%1.43bn
Data delayed at least 15 minutes, as of Nov 28 2022 19:24 GMT.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.